Bussey Carol T, Thaung H P Aye, Hughes Gillian, Bahn Andrew, Lamberts Regis R
Department of Physiology - HeartOtago, Otago School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Exp Physiol. 2018 Aug;103(8):1067-1075. doi: 10.1113/EP087054. Epub 2018 Jun 29.
What is the central question of the study? Is the reduced signalling of AMP-activated protein kinase (AMPK), a key regulator of energy homeostasis in the heart, responsible for the reduced β-adrenergic responsiveness of the heart in obesity? What is the main finding and its importance? Inhibition of AMPK in isolated hearts prevented the reduced cardiac β-adrenergic responsiveness of obese rats, which was accompanied by reduced phosphorylation of AMPK, a proxy of AMPK activity. This suggests a direct functional link between β-adrenergic responsiveness and AMPK signalling in the heart, and it suggests that AMPK might be an important target to restore the β-adrenergic responsiveness in the heart in obesity.
The obesity epidemic impacts heavily on cardiovascular health, in part owing to changes in cardiac metabolism. AMP-activated protein kinase (AMPK) is a key regulator of energy homeostasis in the heart and is regulated by β-adrenoceptors (β-ARs) in normal conditions. In obesity, chronic sympathetic overactivation leads to impaired cardiac β-AR responsiveness, although it is unclear whether AMPK signalling, downstream of β-ARs, contributes to this dysfunction. Therefore, we aimed to determine whether reduced AMPK signalling is responsible for the reduced β-AR responsiveness in obesity. In isolated hearts of lean and obese Zucker rats, we tested β-AR responsiveness to the β -AR agonist isoprenaline (ISO, 1 × 10 to 5 × 10 m) in the absence and presence of the AMPK inhibitor, compound C (CC, 10 μm). The β -AR expression and AMPK phosphorylation were assessed by Western blot. β-Adrenergic responsiveness was reduced in the hearts of obese rats (logEC of ISO-developed pressure dose-response curves: lean -8.53 ± 0.13 × 10 m versus obese -8.35 ± 0.10 × 10 m ; P < 0.05 lean versus obese, n = 6 per group). This difference was not apparent after AMPK inhibition (logEC of ISO-developed pressure curves: lean CC -8.19 ± 0.12 × 10 m versus obese CC 8.17 ± 0.13 × 10 m, P < 0.05, n = 6 per group). β -Adrenergic receptor expression and AMPK phosphorylation were reduced in hearts of obese rats (AMPK at Thr : lean 1.73 ± 0.17 a.u. versus lean CC 0.81 ± 0.13 a.u., and obese 1.18 ± 0.09 a.u. versus obese CC 0.81 ± 0.16 a.u., P < 0.05, n = 6 per group). Thus, a direct functional link between β-adrenergic responsiveness and AMPK signalling in the heart exists, and AMPK might be an important target to restore the reduced cardiac β-adrenergic responsiveness in obesity.
该研究的核心问题是什么?心脏能量稳态的关键调节因子——AMP激活的蛋白激酶(AMPK)信号传导减弱,是否是肥胖状态下心脏β-肾上腺素能反应性降低的原因?主要发现及其重要性是什么?在离体心脏中抑制AMPK可防止肥胖大鼠心脏β-肾上腺素能反应性降低,同时伴有AMPK磷酸化减少,而AMPK磷酸化是AMPK活性的一个指标。这表明心脏中β-肾上腺素能反应性与AMPK信号传导之间存在直接的功能联系,并且提示AMPK可能是恢复肥胖状态下心脏β-肾上腺素能反应性的一个重要靶点。
肥胖流行对心血管健康有严重影响,部分原因是心脏代谢的改变。AMP激活的蛋白激酶(AMPK)是心脏能量稳态的关键调节因子,在正常情况下受β-肾上腺素能受体(β-ARs)调节。在肥胖状态下,慢性交感神经过度激活会导致心脏β-AR反应性受损,尽管尚不清楚β-ARs下游的AMPK信号传导是否导致了这种功能障碍。因此,我们旨在确定AMPK信号传导减弱是否是肥胖状态下β-AR反应性降低的原因。在瘦型和肥胖型 Zucker 大鼠的离体心脏中,我们在不存在和存在AMPK抑制剂化合物C(CC,10 μmol/L)的情况下,测试了β-AR对β-AR激动剂异丙肾上腺素(ISO,1×10至5×10 mol/L)的反应性。通过蛋白质印迹法评估β-AR表达和AMPK磷酸化。肥胖大鼠心脏的β-肾上腺素能反应性降低(ISO产生的压力剂量反应曲线的对数EC:瘦型 -8.53±0.13×10 mol/L 与肥胖型 -8.35±0.10×10 mol/L;每组n = 6,瘦型与肥胖型相比P < 0.05)。在抑制AMPK后,这种差异不明显(ISO产生的压力曲线的对数EC:瘦型CC -8.19±0.12×10 mol/L 与肥胖型CC 8.17±0.13×10 mol/L,每组n = 6,P < 0.05)。肥胖大鼠心脏中β-肾上腺素能受体表达和AMPK磷酸化降低(Thr位点的AMPK:瘦型1.73±0.17任意单位 与瘦型CC 0.81±0.13任意单位,肥胖型1.18±0.09任意单位 与肥胖型CC 0.81±0.16任意单位,每组n = 6,P < 0.05)。因此,心脏中β-肾上腺素能反应性与AMPK信号传导之间存在直接的功能联系,并且AMPK可能是恢复肥胖状态下降低的心脏β-肾上腺素能反应性的一个重要靶点。